A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

November 6, 2026 updated by: GlaxoSmithKline

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.

Study Overview

Study Type

Interventional

Enrollment (Actual)

351

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Cipoletti Rio Negro, Argentina, R8324CVE
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
        • GSK Investigational Site
      • Florida, Argentina, 1602
        • GSK Investigational Site
      • Mar del Plata, Argentina, 7600
        • GSK Investigational Site
      • San Juan, Argentina, J5402DIL
        • GSK Investigational Site
      • Santa Fe, Argentina, 3000
        • GSK Investigational Site
      • Wilrijk, Belgium, 2650
        • GSK Investigational Site
      • Barretos, Brazil, 14784-400
        • GSK Investigational Site
      • Porto Alegre, Brazil, 90610-000
        • GSK Investigational Site
      • São Paulo, Brazil, 01246-000
        • GSK Investigational Site
      • Vitória, Brazil, 29043-260
        • GSK Investigational Site
      • Oulu, Finland, 90220
        • GSK Investigational Site
      • Tampere, Finland, 33520
        • GSK Investigational Site
      • Turku, Finland, 20520
        • GSK Investigational Site
      • Vaasa, Finland, 65130
        • GSK Investigational Site
      • Bordeaux, France, 33076
        • GSK Investigational Site
      • Caen, France, 14033
        • GSK Investigational Site
      • Marseille, France, 13009
        • GSK Investigational Site
      • Quimper, France, 29107
        • GSK Investigational Site
      • Strasbourg, France, 67091
        • GSK Investigational Site
      • Berlin, Germany, 13125
        • GSK Investigational Site
      • Heidelberg, Germany, 69126
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Germany, 45147
        • GSK Investigational Site
    • Schleswig-Holstein
      • Großhansdorf, Schleswig-Holstein, Germany, 22927
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Germany, 07747
        • GSK Investigational Site
      • Athens, Greece, 11528
        • GSK Investigational Site
      • Pylaia Thessaloniki, Greece, 57001
        • GSK Investigational Site
      • Thessaloniki, Greece, 54645
        • GSK Investigational Site
    • Attica
      • Athens, Attica, Greece, 115 27
        • GSK Investigational Site
      • Chaïdári, Attica, Greece, 124 62
        • GSK Investigational Site
    • Central Macedonia
      • Thessaloniki, Central Macedonia, Greece, 570 10
        • GSK Investigational Site
    • Thessaly
      • Larissa, Thessaly, Greece, 411 10
        • GSK Investigational Site
      • Budapest, Hungary, H-1121
        • GSK Investigational Site
      • Gyöngyös, Hungary, 3200
        • GSK Investigational Site
      • Tatabánya, Hungary, 2800
        • GSK Investigational Site
      • Avellino, Italy, 83100
        • GSK Investigational Site
      • Bergamo, Italy, 24125
        • GSK Investigational Site
      • Pisa, Italy, 57124
        • GSK Investigational Site
      • Verona, Italy, 37045
        • GSK Investigational Site
    • GE
      • Genova, GE, Italy, 16132
        • GSK Investigational Site
      • Chiba, Japan, 277-8577
        • GSK Investigational Site
      • Fukuoka, Japan, 812-8582
        • GSK Investigational Site
      • Hyōgo, Japan, 673-8558
        • GSK Investigational Site
      • Kanagawa, Japan, 241-8515
        • GSK Investigational Site
      • Osaka, Japan, 590-0197
        • GSK Investigational Site
      • Saitama, Japan, 350-1298
        • GSK Investigational Site
      • Guadajalara, Mexico, 44280
        • GSK Investigational Site
      • San Luis Potosí City, Mexico, 78209
        • GSK Investigational Site
      • Enschede, Netherlands, 7512 KZ
        • GSK Investigational Site
      • Groningen, Netherlands, 9728 NZ
        • GSK Investigational Site
      • Leeuwarden, Netherlands, 8934 AD
        • GSK Investigational Site
      • Utrecht, Netherlands, 3543 AZ
        • GSK Investigational Site
      • Lublin, Poland, 20-954
        • GSK Investigational Site
      • Prabuty, Poland, 82-550
        • GSK Investigational Site
      • Siedlce, Poland, 08-110
        • GSK Investigational Site
      • Guimarães, Portugal, 4835-044
        • GSK Investigational Site
      • Lisbon, Portugal, 1500-650
        • GSK Investigational Site
      • Lisbon, Portugal, 1998-018
        • GSK Investigational Site
      • Porto, Portugal, 4200-072
        • GSK Investigational Site
      • Vila Nova de Gaia, Portugal, 4434-502
        • GSK Investigational Site
      • Cape Town, South Africa, 7570
        • GSK Investigational Site
      • Parktown, South Africa, 2193
        • GSK Investigational Site
      • Incheon, South Korea, 21565
        • GSK Investigational Site
      • Seoul, South Korea, 03080
        • GSK Investigational Site
      • Seoul, South Korea, 03722
        • GSK Investigational Site
      • Suwon Gyeonggi-do, South Korea, 442-723
        • GSK Investigational Site
      • Badajoz, Spain, 06080
        • GSK Investigational Site
      • Barcelona, Spain, 08035
        • GSK Investigational Site
      • Las Palmas de Gran Canar, Spain, 35016
        • GSK Investigational Site
      • Madrid, Spain, 28041
        • GSK Investigational Site
      • Madrid, Spain, 28046
        • GSK Investigational Site
      • Madrid, Spain, 28027
        • GSK Investigational Site
      • Málaga, Spain, 29010
        • GSK Investigational Site
      • PamplonaNavarra, Spain, 28027
        • GSK Investigational Site
      • Valencia, Spain, 46026
        • GSK Investigational Site
      • Valencia, Spain, 46009
        • GSK Investigational Site
    • Barcelona
      • Badalona, Barcelona, Spain, 08916
        • GSK Investigational Site
      • L'Hospitalet de Llobregat, Barcelona, Spain, 08907
        • GSK Investigational Site
      • Bangkok, Thailand, 10210
        • GSK Investigational Site
      • Chiang Mai, Thailand, 50200
        • GSK Investigational Site
      • Kho Hong Hat Yai, Thailand, 90110
        • GSK Investigational Site
      • Khon Kaen, Thailand, 40002
        • GSK Investigational Site
      • Pathum Thani, Thailand, 12120
        • GSK Investigational Site
      • Ankara, Turkey (Türkiye), 06800
        • GSK Investigational Site
      • Ankara, Turkey (Türkiye), 06680
        • GSK Investigational Site
      • Antalya, Turkey (Türkiye), 07070
        • GSK Investigational Site
      • Istanbul, Turkey (Türkiye), 34214
        • GSK Investigational Site
    • Atakum
      • Samsun, Atakum, Turkey (Türkiye), 55200
        • GSK Investigational Site
      • Abu Dhabi, United Arab Emirates
        • GSK Investigational Site
      • Abu Dhabi, United Arab Emirates, 51900
        • GSK Investigational Site
      • Middlesbrough, United Kingdom, TS4 3BW
        • GSK Investigational Site
      • Wolverhampton, United Kingdom, WV10 0QP
        • GSK Investigational Site
    • Middlesex
      • Northwood, Middlesex, United Kingdom, HA6 2RN
        • GSK Investigational Site
    • Florida
      • Plantation, Florida, United States, 33322-5426
        • GSK Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, United States, 87131
        • GSK Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, United States, 37404
        • GSK Investigational Site
    • West Virginia
      • Morgantown, West Virginia, United States, 26506
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
  • No prior systemic therapy for their locally advanced or metastatic NSCLC
  • Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
  • PD-L1-high (TC/TPS >= 50%) tumor
  • Measurable disease based on RECIST 1.1, as determined by the investigator
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Adequate Baseline organ function
  • Female participants of childbearing potential must use adequate contraception

Exclusion Criteria:

  • Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
  • Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
  • Received prior therapy with any immune checkpoint inhibitors
  • Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
  • Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
  • Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
  • Autoimmune disease or syndrome that required systemic treatment within the past 2 years
  • Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
  • Received any live vaccine <= 30 days prior to first dose of study intervention
  • Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
  • History or evidence of cardiac abnormalities
  • Current unstable liver or biliary disease
  • Severe infection within 4 weeks prior to the first dose of study intervention
  • Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
  • Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
  • Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
  • Has a history of allogeneic tissue/stem cell transplant or solid organ transplant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Pembrolizumab Monotherapy

Participants will be administered with pembrolizumab as monotherapy in a fixed dose.

Pembrolizumab will be administered.

Experimental: Dostarlimab Monotherapy

Participants will be administered with dostarlimab as monotherapy in a fixed dose.

Dostarlimab will be administered

Other Names:
  • GSK4057190
Experimental: Substudy 1A

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A).

Belrestotug will be administered.

Other Names:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Other Names:
  • GSK4057190
Experimental: Substudy 1B

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B).

Belrestotug will be administered.

Other Names:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Other Names:
  • GSK4057190
Experimental: Substudy 1C

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C).

Belrestotug will be administered.

Other Names:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Other Names:
  • GSK4057190
Experimental: Substudy 2A

Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug

Belrestotug will be administered.

Other Names:
  • EOS884448
  • GSK4428859A

Nelistotug will be administered.

Other Names:
  • GSK6097608

Dostarlimab will be administered

Other Names:
  • GSK4057190

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Up to 228 weeks
Up to 228 weeks
Number of Participants with TEAEs or SAEs leading to dose modifications or treatment discontinuation
Time Frame: Up to 228 weeks
Up to 228 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 14, 2022

Primary Completion (Actual)

October 26, 2026

Study Completion (Estimated)

December 6, 2027

Study Registration Dates

First Submitted

September 30, 2022

First Submitted That Met QC Criteria

September 30, 2022

First Posted (Actual)

October 4, 2022

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD Sharing Time Frame

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD Sharing Access Criteria

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe